SCHEMBL3427280

SCHEMBL3427280

CCOC(=O)c1ccc2[nH]c(-c3cc(-c4ccncc4)nnc3OC)c(Br)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.48
PLK4 O00444 1/20 0.48
DAPK3 O43293 1/20 0.48
DYRK3 O43781 1/20 0.48
JAK2 O60674 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
PIM1 P11309 1/20 0.48
RPS6KB1 P23443 1/20 0.48
CDK2 P24941 1/20 0.48
KDR P35968 1/20 0.48
MAPK8 P45983 1/20 0.48
CLK2 P49760 1/20 0.48
GSK3B P49841 1/20 0.48
CDK5 Q00535 1/20 0.48
DYRK1A Q13627 1/20 0.48
PIM3 Q86V86 1/20 0.48
MINK1 Q8N4C8 1/20 0.48
AURKB Q96GD4 1/20 0.48
PBK Q96KB5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428101 0.83 MAPK1 (0.43) MAPK1PLK4DAPK3DYRK3JAK2
SCHEMBL3425296 0.83 MAPK1 (0.52) MAPK1PLK4DAPK3DYRK3JAK2
SCHEMBL3424712 0.81 PKN1 (0.51) MAPK1CDK5IMPDH2KDM4EMAPT
SCHEMBL1750565 0.71 TLR7 (0.48) IMPDH2MAPTTUBB4ATUBBTUBA3C
SCHEMBL3424201 0.70 HRH3 (0.42) MAPK1IMPDH2KDM4EMAPTALDH1A1
SCHEMBL3428249 0.70 TUBB4A (0.40) GSK3BIMPDH2KDM4EALDH1A1HSD17B10
SCHEMBL3421159 0.69 ALOX5 (0.39) IMPDH2KDM4EALDH1A1HSD17B10HPGD
Methyl Alcohol SCHEMBL1749949 0.69 TUBB4A (0.41) PLK4DYRK1AIMPDH2KDM4EMAPT
SCHEMBL1751468 0.69 TUBB4A (0.46) MAPK1DYRK1AIMPDH2KDM4EMAPT
SCHEMBL3425635 0.68 ALOX5 (0.43) GSK3BCDK5KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753743-B1 PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS DEUTSCHLAND (DE) 2015-03-04 EP disclosed
US-7709466-B2 Pyridazinone derivatives, methods for their production and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-19 US disclosed
EP-1753743-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis Deutschland GmbH (DE) 2007-02-21 EP disclosed
WO-2005111018-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS GSK3B, GSK3A, PDXK MAPK1 200/4885PLK4 12/4885DAPK3 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.